AbbVie PE Ratio 2010-2019 | ABBV

Current and historical p/e ratio for AbbVie (ABBV) from 2010 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. AbbVie PE ratio as of September 16, 2019 is 8.35.
AbbVie PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-09-17 71.60 26.32
2019-06-30 72.72 $2.72 26.74
2019-03-31 80.59 $3.49 23.09
2018-12-31 91.04 $3.58 25.43
2018-09-30 92.42 $4.84 19.10
2018-06-30 89.64 $4.04 22.19
2018-03-31 90.63 $3.97 22.83
2017-12-31 91.94 $3.29 27.95
2017-09-30 83.89 $4.11 20.41
2017-06-30 67.85 $4.07 16.67
2017-03-31 60.37 $3.86 15.64
2016-12-31 57.42 $3.63 15.82
2016-09-30 57.30 $3.70 15.49
2016-06-30 55.75 $3.47 16.07
2016-03-31 50.95 $3.32 15.35
2015-12-31 52.26 $3.12 16.75
2015-09-30 47.54 $1.69 28.13
2015-06-30 58.28 $1.26 46.26
2015-03-31 50.36 $1.11 45.37
2014-12-31 55.87 $1.09 51.25
2014-09-30 48.94 $2.30 21.28
2014-06-30 47.45 $2.59 18.32
2014-03-31 42.83 $2.57 16.67
2013-12-31 43.65 $2.56 17.05
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $104.248B $32.753B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $345.150B 15.03
Roche Holding AG (RHHBY) Switzerland $236.204B 0.00
Merck (MRK) United States $211.513B 17.39
Pfizer (PFE) United States $204.151B 12.02
Novartis AG (NVS) Switzerland $199.581B 17.16
Novo Nordisk (NVO) Denmark $117.216B 20.71
AstraZeneca (AZN) United Kingdom $112.218B 21.71
Sanofi (SNY) France $109.456B 13.45
Eli Lilly (LLY) United States $107.057B 19.98
GlaxoSmithKline (GSK) United Kingdom $101.988B 12.82
Bristol-Myers Squibb (BMY) United States $80.856B 11.47
Bayer (BAYRY) Germany $70.165B 10.22
H Lundbeck (HLUYY) Denmark $6.958B 10.04